EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 17 Issue 4
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout: Bloomberg

It wasn't long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn't come together, and the biotech eventually so...
26 October 2021 Regional News Acceleron | Acceleron Pharma
Continue Reading →
Regional News

Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180

Merck's new CEO Robert Davis has big shoes to fill after taking the reins from Kenneth Frazier at the start of July. Just two weeks into his tenure, though, his compa...
13 October 2021 Regional News Acceleron | buyout
Continue Reading →
Regional News

Merck’s reported $11B Acceleron buy could help it diversify beyond Keytruda, but antitrust hurdles loom

Merck has emerged as a finalist to acquire Acceleron for around $11 billion. The deal dovetails with the Big Pharma company’s plan to diversify beyond its immuno-onco...
29 September 2021 Regional News Acceleron | immuno-oncology
Continue Reading →
Catalyst: 12th January 2026
Quotient

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2026, All Rights Reserved – Powered by Teksyte